心血管疾患における様々なメチル化修飾の役割
Yuan Lin1,2,3,4, Jennifer Wang5, Xin Liu1,2,3
1State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), College of Pharmacy, and Department of Cardiology, the Second Affiliated Hospital, Harbin Medical University, Harbin, 150081, China.
Frontiers of medicine
|December 26, 2025
まとめ
DNA、タンパク質、RNA N⁶-メチルアデノシン(m⁶A)の変化を含むエピジェネティックメチル化修飾は、心血管疾患の発症において重要です。これらのエピジェネティックメカニズムを理解することは、心疾患の新たな治療標的を提供します。
科学分野:
- 分子生物学
- 心臓病学
- エピジェネティクス
背景:
- 心血管疾患(CVD)は、世界的な死亡と障害の主な原因です。
- 効果的な予防と治療には、分子メカニズムの深い理解が必要です。
- エピジェネティック修飾、特にメチル化は、CVDの病因においてますます認識されています。
研究 の 目的:
- DNA、タンパク質、RNA N⁶-メチルアデノシン(m⁶A)メチル化の生物学的プロセスをレビューすること。
- これらのメチル化修飾が主要な心血管疾患において果たす役割を要約すること。
- エピジェネティックメカニズムをCVDの治療および診断標的として強調すること。
主な方法:
- エピジェネティクス研究の最近の進歩に関する文献レビュー。
- メチル化修飾(DNAメチル化、タンパク質メチル化、m⁶A RNA修飾)に焦点を当てる。
- 心肥大、心不全、虚血性心疾患、アテローム性動脈硬化症を含むCVDに関連する所見の統合。
主要な成果:
- メチル化修飾は、心血管の健康に関連する遺伝子発現に大きな影響を与えます。
- DNA、タンパク質、m⁶Aメチル化の特定の役割が、心肥大、心不全、虚血性心疾患、アテローム性動脈硬化症で特定されています。
- エピジェネティックな変化は、様々な心血管状態の進行と病因に関与しています。
結論:
- エピジェネティックメチル化修飾は、心血管疾患の発症と進行に不可欠です。
- これらのメチル化メカニズムを標的とすることは、心臓病学における新しい診断および治療戦略のための有望な道を開きます。
- エピジェネティック調節に関するさらなる研究は、心血管医学を進歩させるために不可欠です。
関連する概念動画
Epigenetic Regulation
3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.7K
Epigenetic Regulation
33.4K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.4K
Phase II Reactions: Methylation Reactions
655
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
655
Coronary Artery Disease I: Introduction
846
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
846
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516
Atherosclerosis III: Management
291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291


